NCT03362294 - Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions

Primary Progressive Multiple Sclerosis

Interventions

DRUG

GA Depot 40mg once monthly

Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)

DRUG

GA Depot 25mg once monthly

Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)

Trial Locations (7)

Mapi Pharma Research site 09, Haifa

Mapi Pharma Research site 07, Jerusalem

Mapi Pharma Research site 08, Petah Tikva

Mapi Pharma Research site 06, Rehovot

Mapi Pharma Research site 01, Tel Aviv

Mapi Pharma Research site 20, Chisinau

Mapi Pharma Research site 22, Chisinau